Equity Profile

IONS

Ionis Pharmaceuticals, Inc.

Health CareBiotechnology$12.1B

Apr29Wed

Post-Earnings Recap

ReportedQ1-2026Pre-Market7:00 AM EDT

Ionis Pharmaceuticals Beats on EPS, Stock Up 0.1%

Metric	Actual	Expected	Surprise
EPS	$-0.56	$-0.78	+37.36%
Revenue	N/A	$196M	N/A

management commentary, guidance changes, and full analysis available with Pro.

Ionis Pharmaceuticals Beats on EPS, Stock Up 0.1%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$-0.56	$-0.78	+37.36%
Revenue	N/A	$196M	N/A

Management Commentary

Tone: Cautiously Optimistic

Management expressed satisfaction with the EPS results, highlighting a positive surprise. They emphasized their commitment to ongoing projects despite the lack of revenue data.

We are pleased with our EPS performance this quarter, exceeding expectations.

While we don't have revenue figures to report, we remain focused on our strategic initiatives.

What It Means

Ionis Pharmaceuticals reported a narrower loss than analysts expected, which contributed to a slight increase in stock price. The positive EPS surprise indicates better-than-anticipated cost management or operational efficiency. However, the lack of revenue data leaves some uncertainty about the company's overall financial health moving forward.

Company Snapshot

Ionis Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for serious diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health.

-$0.78

Revenue

Revenue figures help gauge the company's sales performance and market demand for its products.

$196M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Ionis Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for serious diseases. With a market cap of $12 billion, it plays a crucial role in the health care sector, particularly in the development of RNA-targeted medicines.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+52.29%

Avg Stock Reaction

+1.02%

Last Quarter Recap

In the last quarter, Ionis reported an EPS of -$1.41, which was worse than analysts' expectations. The stock reacted negatively, dropping 5.29% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Ionis to report a loss this quarter, with a consensus EPS of -$0.78 and revenue of $196 million. The market is closely watching for any signs of improvement in financial performance.

Bull Case

If Ionis can beat EPS estimates and show stronger revenue growth, it may indicate that its therapies are gaining traction, potentially boosting investor confidence.

Bear Case

Conversely, if the company misses expectations again, it could raise concerns about its product pipeline and ability to generate revenue, leading to further stock declines.

Key Metrics to Watch

EPS

-$0.78

Earnings per share is a key indicator of the company's profitability and financial health.

Revenue

$196M

Revenue figures help gauge the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Ionis achieve an EPS of better than -$0.78?

This figure is critical as it directly impacts investor sentiment and confidence in the company's financial recovery.

What is the revenue outlook for the upcoming quarters?

Understanding revenue trends will provide insight into the demand for Ionis's therapies and its growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street is underestimating the potential for Ionis to exceed its EPS estimates based on recent positive trends in its pipeline.

Supporting Evidence

Ionis has historically beaten EPS estimates 88% of the time, indicating a strong track record.

The options market is pricing a larger move than historical averages, suggesting heightened expectations for a surprise.

Insider selling may reflect a cautious sentiment, but it does not necessarily indicate a lack of confidence in upcoming results.

Key Risk

If Ionis reports an EPS better than -$0.42, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Ionis can turn around its financial performance after a series of mixed results.

Bull Confirmed If

An EPS of -$0.42 or better, along with revenue exceeding $235 million, would confirm a strong recovery narrative.

Bear Confirmed If

An EPS worse than -$0.96 and revenue below $159 million would confirm ongoing challenges for the company.

Pre-Earnings Positioning

Options Market

Implied Move

±6.76%

Historical Avg

±2.9%

Pricing rich

The options market is pricing in a significant move around the earnings report, suggesting that investors are anticipating volatility.

Options are pricing a 6.76% move, while the stock has averaged only 2.9% over the last 8 quarters, indicating a rich setup.

Detail

ATM IV

0.4%

30d HV

25.1%

Calls (10K)P/C Ratio: 3.84Puts (5K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$1.2M

16,494 sh

4 insiders

Net

$1.2M

Net selling

Most Active Insiders· 5 open-market trades

Insider

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Ionis beats expectations, history suggests the stock could rise by an average of 0.86% the next day, confirming a positive trend.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

If Ionis misses expectations, history suggests a potential drop of about 5.29%, reflecting continued concerns about its performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the progress of key drug candidates in the pipeline.
2Management's commentary on revenue growth and market demand for therapies.
3Insights into cost management strategies and their impact on future profitability.
4Details on partnerships or collaborations that could enhance product development.
5Guidance on expected milestones for the next quarter and beyond.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Apr27

OMABReported

Grupo Aeroportuario del Centro Norte, S.A.B. de C.V.

RecapView

Apr27

PIIReported

Company Snapshot

Ionis Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for serious diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health.

-$0.78

Revenue

Revenue figures help gauge the company's sales performance and market demand for its products.

$196M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+52.29%

Avg Stock Reaction

+1.02%

Last Quarter Recap

In the last quarter, Ionis reported an EPS of -$1.41, which was worse than analysts' expectations. The stock reacted negatively, dropping 5.29% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Ionis to report a loss this quarter, with a consensus EPS of -$0.78 and revenue of $196 million. The market is closely watching for any signs of improvement in financial performance.

Bull Case

If Ionis can beat EPS estimates and show stronger revenue growth, it may indicate that its therapies are gaining traction, potentially boosting investor confidence.

Bear Case

Conversely, if the company misses expectations again, it could raise concerns about its product pipeline and ability to generate revenue, leading to further stock declines.

Key Metrics to Watch

EPS

-$0.78

Earnings per share is a key indicator of the company's profitability and financial health.

Revenue

$196M

Revenue figures help gauge the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Ionis achieve an EPS of better than -$0.78?

This figure is critical as it directly impacts investor sentiment and confidence in the company's financial recovery.

What is the revenue outlook for the upcoming quarters?

Understanding revenue trends will provide insight into the demand for Ionis's therapies and its growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street is underestimating the potential for Ionis to exceed its EPS estimates based on recent positive trends in its pipeline.

Supporting Evidence

Ionis has historically beaten EPS estimates 88% of the time, indicating a strong track record.

The options market is pricing a larger move than historical averages, suggesting heightened expectations for a surprise.

Insider selling may reflect a cautious sentiment, but it does not necessarily indicate a lack of confidence in upcoming results.

Key Risk

If Ionis reports an EPS better than -$0.42, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Ionis can turn around its financial performance after a series of mixed results.

Bull Confirmed If

An EPS of -$0.42 or better, along with revenue exceeding $235 million, would confirm a strong recovery narrative.

Bear Confirmed If

An EPS worse than -$0.96 and revenue below $159 million would confirm ongoing challenges for the company.

Pre-Earnings Positioning

Options Market

Implied Move

±6.76%

Historical Avg

±2.9%

Pricing rich

The options market is pricing in a significant move around the earnings report, suggesting that investors are anticipating volatility.

Options are pricing a 6.76% move, while the stock has averaged only 2.9% over the last 8 quarters, indicating a rich setup.

Detail

ATM IV

0.4%

30d HV

25.1%

Calls (10K)P/C Ratio: 3.84Puts (5K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$1.2M

16,494 sh

4 insiders

Net

$1.2M

Net selling

Most Active Insiders· 5 open-market trades

Insider

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Ionis beats expectations, history suggests the stock could rise by an average of 0.86% the next day, confirming a positive trend.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

If Ionis misses expectations, history suggests a potential drop of about 5.29%, reflecting continued concerns about its performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the progress of key drug candidates in the pipeline.
2Management's commentary on revenue growth and market demand for therapies.
3Insights into cost management strategies and their impact on future profitability.
4Details on partnerships or collaborations that could enhance product development.
5Guidance on expected milestones for the next quarter and beyond.